CD274 and neoplasm: Clinical trial NCT02054806 was a phase Ib study of a cohort of 24 patients, expressing PD-L1 on tumor or stromal cells, with advanced cervical squamous cell cancer, in which pembrolizumab was found to be well tolerated and having some clinical efficacy [141].